 | • レポートコード：D0-MOR-AP0979 • 出版社/出版日：Mordor Intelligence / 2020年4月20日 • レポート形態：英文、PDF、114ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：健康管理 |
| Single User | ￥629,000 (USD4,250) | ▷ お問い合わせ |
| Team User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Corporate License | ￥1,110,000 (USD7,500) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 本調査レポートは、腎臓除神経装置の世界市場について調査・分析した資料で、腎臓除神経装置の市場概要、動向、セグメント別市場規模、地域別分析、競争状況、企業情報、市場機会分析などで構成されています。 |
The major factors for the growth of the renal denervation devices market include the rising prevalence of hypertension and long-lasting effect of the procedure.High blood pressure is called hypertension. The prevalence of hypertension has observed a significant rise, over the past few years. Generally, blood pressure rises and falls throughout the day, but it can damage one’s heart and result in health problems, if hypertension stays high for a long time.
According to the CDC (Centers for Disease Control and Prevention), about 75 million American adults (32%) have high blood pressure (hypertension), but only about half (54%) of them, with high blood pressure, have their condition under control. High blood pressure was a primary contributing cause of death for more than 410,000 Americans, in 2014. CDC also stated that high blood pressure costs the country USD 48.6 billion, every year. The high prevalence is not just limited to the United States, owing to the fact that the European and South Asian countries also have a high rate of hypertension, makes this a global problem.
– On the other hand, only a few renal denervation devices are approved in Europe, while the major players are gaining approval for the clinical trials from the FDA, in the United States. Thus, owing to all of the aforementioned factors, the market studied is expected to witness high growth, in the next coming years.
Key Market Trends
The Ultrasound-based Segment is Expected to be the Fastest Growing Segment
The ultrasound-based renal denervation devices are a minimally invasive procedure, using ultrasound to ablate nerves in the wall of the renal arteries, and it disrupts the transmission of nerve impulses to and from the kidney and lowers blood pressure. Additionally, according to the first randomized trial to compare the techniques (RADIOSOUND-HTN trial), the ultrasound-based renal denervation (RDN) approach led to greater reductions in the blood pressure than radiofrequency ablation in patients, with resistant hypertension. The rising prevalence of hypertension is expected to boost the overall growth of the market.
Europe is Expected to Dominate the Market
Europe is found to hold a major share for the renal denervation devices market, and it is expected to show a similar trend over the forecast period, without significant fluctuations. According to the data published by the Public Health England, high blood pressure affects more than 1 in 4 adults in England. There is a large number of renal denervation devices, which have received CE approval, in Europe. The major factor driving the growth of the market is rising R&D activities for the development of efficient devices. As per the clinicaltrials.gov, one of the market players, Abbott Medical Devices, completed the observational study of the EnligHTN renal denervation system, in Europe, in February 2019. Additionally, rising cases of drug-resistant hypertension may boost the overall growth of the market, over the forecast period.
Competitive Landscape
The market studied is a consolidated market, owing to the presence of some major market players. Some of the market players are Abbott, Ablative Solutions, Boston Scientific Corporation, CardioSonic, Kona Medical, Medtronic PLC, Mercator MedSystems, ReCor Medical, and Symple Surgical.
Reasons to Purchase this report:
– The market estimate (ME) sheet in Excel format
– 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Hypertension
4.2.2 Long Lasting Effect of the Procedure
4.3 Market Restraints
4.3.1 Painful Procedure
4.3.2 Stringent Approval Process for Renal Denervation Devices
4.4 Porter’s Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Technology
5.1.1 Radiofrequency-based
5.1.2 Ultrasound-based
5.1.3 Micro-infusion-based
5.2 Geography
5.2.1 North America
5.2.1.1 United States
5.2.1.2 Canada
5.2.1.3 Mexico
5.2.2 Europe
5.2.2.1 Germany
5.2.2.2 United Kingdom
5.2.2.3 France
5.2.2.4 Italy
5.2.2.5 Spain
5.2.2.6 Rest of Europe
5.2.3 Asia-Pacific
5.2.3.1 China
5.2.3.2 Japan
5.2.3.3 India
5.2.3.4 Australia
5.2.3.5 South Korea
5.2.3.6 Rest of Asia-Pacific
5.2.4 Middle East & Africa
5.2.4.1 Gulf Cooperation Council
5.2.4.2 South Africa
5.2.4.3 Rest of Middle East & Africa
5.2.5 South America
5.2.5.1 Brazil
5.2.5.2 Argentina
5.2.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Medtronic PLC
6.1.2 St. Jude Medical Inc.
6.1.3 ReCor Medical Inc.
6.1.4 Ablative Solutions Inc.
6.1.5 Cardiosonic Ltd
6.1.6 Mercator MedSystems
6.1.7 Terumo Corporation
6.1.8 Symple Surgical
6.1.9 Renal Dynamics Limited
7 MARKET OPPORTUNITIES AND FUTURE TRENDS